Veracyte, Inc. (VCYT)

Market Cap	3.17B
Revenue (ttm)	425.33M
Net Income (ttm)	-9.27M
Shares Out	77.50M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	44.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,680,655
Open	38.53
Previous Close	39.07
Day's Range	38.44 - 41.37
52-Week Range	18.61 - 46.00
Beta	1.70
Analysts	Buy
Price Target	39.86 (-2.52%)
Earnings Date	Nov 6, 2024

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 815
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Financial Performance

In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $39.86, which is a decrease of -2.52% from the latest price.

Price Target

$39.86

(-2.52% downside)

Analyst Consensus: Buy